RU2650778C2 - Композиции и способы применения для определения не4а - Google Patents

Композиции и способы применения для определения не4а Download PDF

Info

Publication number
RU2650778C2
RU2650778C2 RU2013142334A RU2013142334A RU2650778C2 RU 2650778 C2 RU2650778 C2 RU 2650778C2 RU 2013142334 A RU2013142334 A RU 2013142334A RU 2013142334 A RU2013142334 A RU 2013142334A RU 2650778 C2 RU2650778 C2 RU 2650778C2
Authority
RU
Russia
Prior art keywords
he4a
antibody
polypeptide
ovarian cancer
antibodies
Prior art date
Application number
RU2013142334A
Other languages
English (en)
Russian (ru)
Other versions
RU2013142334A (ru
Inventor
Инжгерд ХЭЛЛСТРОМ
Карл-Эрик ХЭЛЛСТРОМ
Джон РЭЙКРАФТ
Кристиан ФЕРМЕР
Ева Ройжер
Original Assignee
Фуджиребио Диагностикс, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фуджиребио Диагностикс, Инк filed Critical Фуджиребио Диагностикс, Инк
Publication of RU2013142334A publication Critical patent/RU2013142334A/ru
Application granted granted Critical
Publication of RU2650778C2 publication Critical patent/RU2650778C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2013142334A 2011-02-17 2011-02-17 Композиции и способы применения для определения не4а RU2650778C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/025321 WO2012112160A1 (en) 2011-02-17 2011-02-17 Compositions and methods of use for determination of he4a

Publications (2)

Publication Number Publication Date
RU2013142334A RU2013142334A (ru) 2015-03-27
RU2650778C2 true RU2650778C2 (ru) 2018-04-17

Family

ID=46672864

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013142334A RU2650778C2 (ru) 2011-02-17 2011-02-17 Композиции и способы применения для определения не4а

Country Status (12)

Country Link
US (3) US9822169B2 (enExample)
EP (1) EP2675911B1 (enExample)
JP (1) JP5887364B2 (enExample)
KR (3) KR101854110B1 (enExample)
CN (1) CN103492582B (enExample)
AU (1) AU2011359350B2 (enExample)
BR (1) BR112013021056B1 (enExample)
CA (1) CA2827618C (enExample)
ES (1) ES2834617T3 (enExample)
IL (1) IL227924B (enExample)
RU (1) RU2650778C2 (enExample)
WO (1) WO2012112160A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
ES2834617T3 (es) * 2011-02-17 2021-06-18 Fujirebio Diagnostics Inc Composiciones y métodos de uso para la determinación de HE4a
CN106432492A (zh) * 2015-08-07 2017-02-22 广州瑞博奥生物技术有限公司 针对肿瘤标志物建立的抗体组合及其elisa方法
JP6613490B2 (ja) * 2016-02-19 2019-12-04 国立大学法人 宮崎大学 腺癌の検出方法
USD922352S1 (en) 2019-01-04 2021-06-15 Dolby Laboratories Licensing Corporation Speaker
JP7539369B2 (ja) * 2019-04-02 2024-08-23 大塚製薬株式会社 病態情報生成方法、病態情報生成システム、ｈｅ４糖鎖分析キット及びｈｅ４
CN111620939B (zh) * 2019-10-25 2021-01-01 南京市妇幼保健院 一种用于治疗或辅助治疗卵巢癌的多肽zyx36-58
USD940793S1 (en) * 2019-11-22 2022-01-11 Microsoft Corporation Electronic device
JPWO2021261483A1 (enExample) * 2020-06-23 2021-12-30
US20240353411A1 (en) * 2022-04-08 2024-10-24 Ajou University Industry-Academic Cooperation Foundation He4 detecting peptide and use thereof
CN117487018B (zh) * 2023-09-27 2024-05-17 武汉爱博泰克生物科技有限公司 抗人附睾分泌蛋白4的兔单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003021273A2 (en) * 2001-08-29 2003-03-13 Pacific Northwest Research Institute Diagnosis of carcinomas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
PL1620082T3 (pl) * 2003-05-05 2010-10-29 Probiodrug Ag Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa
JP4744109B2 (ja) 2004-07-20 2011-08-10 トヨタ自動車株式会社 半導体装置とその製造方法
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
ATE408828T1 (de) * 2005-02-16 2008-10-15 Dana Farber Cancer Inst Inc Verfahren zur erkennung eines ovarialkarzinoms
US20070286865A1 (en) 2006-01-04 2007-12-13 Richard Moore Use of HE4 and other biochemical markers for assessment of ovarian cancers
JP2009524438A (ja) * 2006-01-27 2009-07-02 トライパス イメージング インコーポレイテッド 卵巣癌を有する可能性の高い患者を同定するための方法およびそのための組成物
EP2121761A1 (en) * 2007-03-09 2009-11-25 Tripath Imaging, Inc. He4 monoclonal antibodies and methods for their use
US8455189B2 (en) 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
MX2013002268A (es) * 2010-08-26 2014-02-03 Univ Washington Ct Commerciali Metodos para detectar anticuerpos anti-he4 y metodos de diagnosis y/o de prognosis de condiciones asociadas con celulas que expresan he4.
ES2834617T3 (es) * 2011-02-17 2021-06-18 Fujirebio Diagnostics Inc Composiciones y métodos de uso para la determinación de HE4a
WO2012170513A2 (en) * 2011-06-06 2012-12-13 Women & Infants' Hospital Of Rhode Island He4 based therapy for malignant disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003021273A2 (en) * 2001-08-29 2003-03-13 Pacific Northwest Research Institute Diagnosis of carcinomas

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BINGLE L. et al., The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene, 2002, vol.21, pp.2768-2773. *
BINGLE L. et al., The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene, 2002, vol.21, pp.2768-2773. HELLSTROM I. et al., The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma, Cancer Res 2003, vol.63, pp.3695-3700. АЛЬТШУЛЕР E.П. и др. Получение рекомбинантных антител и способы увеличения их аффинности. Успехи биологической химии, 2010, т.50, с.203-258. *
HELLSTROM I. et al., The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma, Cancer Res 2003, vol.63, pp.3695-3700. АЛЬТШУЛЕР E.П. и др. Получение рекомбинантных антител и способы увеличения их аффинности. Успехи биологической химии, 2010, т.50, с.203-258. *

Also Published As

Publication number Publication date
US20180057575A1 (en) 2018-03-01
AU2011359350B2 (en) 2016-07-14
US20200325215A1 (en) 2020-10-15
CN103492582A (zh) 2014-01-01
JP5887364B2 (ja) 2016-03-16
RU2013142334A (ru) 2015-03-27
AU2011359350A2 (en) 2014-05-01
US9822169B2 (en) 2017-11-21
WO2012112160A1 (en) 2012-08-23
AU2011359350A1 (en) 2013-09-12
EP2675911A1 (en) 2013-12-25
US20150353629A1 (en) 2015-12-10
KR20200013118A (ko) 2020-02-05
ES2834617T3 (es) 2021-06-18
CA2827618C (en) 2019-08-06
JP2014507153A (ja) 2014-03-27
CA2827618A1 (en) 2012-08-23
IL227924A0 (en) 2013-09-30
KR20180014239A (ko) 2018-02-07
KR101854110B1 (ko) 2018-05-04
KR102074141B1 (ko) 2020-02-07
BR112013021056A2 (pt) 2016-08-09
IL227924B (en) 2019-01-31
KR20140025348A (ko) 2014-03-04
CN103492582B (zh) 2016-06-22
EP2675911A4 (en) 2015-04-01
EP2675911B1 (en) 2020-11-04
BR112013021056B1 (pt) 2022-03-29

Similar Documents

Publication Publication Date Title
JP5887364B2 (ja) ＨＥ４ａの測定のための組成物および使用方法
JP5188443B2 (ja) 癌腫の診断
RU2312109C2 (ru) Моноклональное антитело и продуцирующая его гибридома
JP4813661B2 (ja) 癌を診断するための方法および組成物
US6770445B1 (en) Methods and compositions for diagnosing carcinomas
JP4532273B2 (ja) 癌に関係するタンパク質
WO2022007283A1 (zh) 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
JP2014532408A (ja) ＵＳＰ２ａペプチドおよび抗体
JP2022521534A (ja) 乳がんのバイオマーカとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用
HK1191056B (en) Compositions and methods of use for determination of he4a
US20070141061A1 (en) Protein involved in carcinoma
HK1214346B (en) Diagnosis of ovarian carcinoma